Table 1.

Contemporary series of radiosurgery alone in single (SRS) or fractionated stereotactic radiotherapy (FSRT) for recurrent high-grade gliomas.

Author	Year	N	Median target volume (ml)	Median fraction number, prescription dose	Median OS after re-RT (months)	Toxicity
Eliott et al. [35].	2011	26	1.22	1 fx, 15 Gy	13.5	RN 7.7 %; RTOG Grade4 3.8 %
Maranzano et al. [36].	2011	SRS 13 FSRT 9	SRS 5.3 FSRT 44	SRS 17 Gy FSRT 10 fx, 30 Gy	11	RN 23 %
Conti et al. [34]	2012	11	N/A	2 fx, 20 Gy or 3–5 fx, 24–25 Gy	7	Corticosteroid dependency 63 %
Skeie et al. [37]	2012	51	N/A	1 fx, 12.2 Gy	12	Complications 9.8 %
Koga et al. [38]	2012	9 (Group A); 9 (Group B)	15 (A); 13 (B)	1 fx, 20 Gy (A); 1fx, 20 Gy (margin dose) (B)	10.5 (A); 9 (B)	RN 6.5% (A); RN 29% (B)
McKenzie et al. [39]	2012	35	8.54	5 fx, 30 Gy	8.6	RTOG (G3–G4) 9 %
Martínez-Carrillo et al. [40]	2014	87	6	1 fx, 18 Gy	10	NONE
Anand et al. [41]	2014	16	NA	5–6 fx, 30 Gy	9.3	RTOG > G1 6.2 %
Pinzi et al. [25]	2015	SRS 42 FSRT 67	SRS 2 FSRT 11	SRS 15 Gy FSRT 3 fx, 23 Gy	11.5	RN 6%

mOS: median overall survival, ReRT: Re-irradiation, SRS: radiosurgery, FSRT: fractionated stereotactic radiotherapy (multisession radiosurgery), RTOG: radiation therapy oncology group, G: toxicity grade, N/A: not available, BN: brain necrosis, fx: fraction(s).